DPM2 Gene (Dolichol-Phosphate Mannosyltransferase Subunit 2)

Migration, Crosslink

📖

DPM2 Gene (Dolichol-Phosphate Mannosyltransferase Subunit 2)

active

wiki page Created: 2026-04-02T07:19:24 By: crosslink-migration Quality: 50% ✓ SciDEX ID: wiki-genes-dpm2

📖 Wiki Page

gene1826 wordssynced 2026-04-02

DPM2 Gene (Dolichol-Phosphate Mannosyltransferase Subunit 2)

Overview

...

DPM2 Gene (Dolichol-Phosphate Mannosyltransferase Subunit 2)

Overview

Mermaid diagram (expand to render)

<table class="infobox infobox-gene">
<tr>
<th class="infobox-header" colspan="2">DPM2 Gene (Dolichol-Phosphate Mannosyltransferase Subunit 2)</th>
</tr>
<tr>
<td class="label">Mutation</td>
<td>Effect</td>
</tr>
<tr>
<td class="label">c.62G>A</td>
<td>p.Trp21*</td>
</tr>
<tr>
<td class="label">c.100C>T</td>
<td>p.Arg34*</td>
</tr>
<tr>
<td class="label">c.178G>A</td>
<td>p.Gly60Arg</td>
</tr>
<tr>
<td class="label">c.220delC</td>
<td>p.Leu74Cfs*</td>
</tr>
<tr>
<td class="label">Associated Diseases</td>
<td><a href="/wiki/als" style="color:#ef9a9a">Als</a>, <a href="/wiki/ms" style="color:#ef9a9a">Ms</a></td>
</tr>
<tr>
<td class="label">KG Connections</td>
<td><a href="/atlas" style="color:#4fc3f7">15 edges</a></td>
</tr>
</table>

Gene Symbol: DPM2 Full Name: Dolichol-Phosphate Mannosyltransferase Subunit 2 Chromosomal Location: 9q34.11 NCBI Gene ID: [8769](https://www.ncbi.nlm.nih.gov/gene/8769) OMIM: [605143](https://www.omim.org/entry/605143) Ensembl ID: ENSG00000110693 UniProt: [O95477](https://www.uniprot.org/uniprot/O95477)

Function

The DPM2 gene encodes a regulatory subunit of the dolichol-phosphate mannose (DPM) synthase complex[@schenk2001]. DPM2 serves as a critical regulator of the DPM complex, which consists of DPM1 (catalytic subunit), DPM2 (regulatory subunit), and DPM3 (scaffold subunit). Together, these subunits catalyze the synthesis of dolichol-phosphate mannose (DPM), an essential donor substrate for protein glycosylation[@kinoshita2009].

Regulatory Function

DPM2 plays several important regulatory roles:

Complex Assembly: DPM2 is essential for proper assembly of the DPM synthase complex
Enzyme Activity: DPM2 modulates the catalytic activity of DPM1
Subcellular Localization: DPM2 helps localize the complex to the endoplasmic reticulum membrane
Quality Control: DPM2 ensures proper folding and stability of the complex

Glycosylation Pathway

The DPM synthase complex is crucial for:

N-linked Glycosylation: Transfer of mannose to nascent polypeptides in the ER
GPI Anchor Biosynthesis: Synthesis of glycosylphosphatidylinositol anchors
C-mannosylation: Rare post-translational modification of tryptophan residues

Protein Structure and Function

DPM Complex Architecture

The dolichol-phosphate mannose (DPM) synthase complex consists of three subunits that work together[@liu2023]:

DPM1: Catalytic subunit (~40 kDa), contains the active site for mannose transfer
DPM2: Regulatory subunit (~9 kDa), essential for complex stability and activity modulation
DPM3: Scaffold subunit (~12 kDa), anchors the complex to the ER membrane

Subunit Interactions

The DPM complex exhibits specific subunit interactions:

DPM2-DPM3 interaction: Critical for complex assembly and ER membrane anchoring

DPM2-DPM1 interaction: Modulates catalytic activity of DPM1

DPM1-DPM3 interaction: Positions the catalytic site for dolichol-phosphate access

Regulatory Functions of DPM2

DPM2 serves multiple regulatory roles beyond complex formation:

Enzyme kinetics: Adjusts Vmax and Km of the mannosyltransferase reaction
Substrate channeling: Directs dolichol-phosphate to the active site
Quality control: Ensures proper folding and prevents aggregation
Cellular localization: Targets the complex to ER membrane microdomains

Alzheimer's Disease

DPM2 and the glycosylation pathway are relevant to Alzheimer's disease[@hanna2019][@schwarz2024][@yamamoto2023]:

APP Glycosylation: Proper glycosylation affects [amyloid precursor protein](/entities/app-protein) processing[@kelley2020][@schwarz2024]
[Tau](/proteins/tau) Pathology: Glycosylation abnormalities in tauopathies[@wen2022]
Synaptic Dysfunction: Glycosylation of synaptic proteins is essential for proper synaptic function[@appoh2005][@schwarz2024]
ER Stress: Impaired glycosylation can trigger endoplasmic reticulum stress response[@masri2018]

Parkinson's Disease

[Alpha-Synuclein](/proteins/alpha-synuclein) Modifications: Post-translational glycosylation affects alpha-synuclein aggregation[@chaitankar2020]
Protein Quality Control: Glycosylation defects impact cellular protein homeostasis
Dopaminergic Vulnerability: Glycosylation may influence neuronal susceptibility

Congenital Disorders of Glycosylation

DPM2 mutations cause Congenital Disorder of Glycosylation Type I (CDG), characterized by:

Severe Neurological Impairment: Developmental delay, intellectual disability
Seizures: Epileptic activity in affected individuals
Dystonia: Movement disorders in some patients
Systemic Manifestations: Coagulopathy, dysmorphic features

Expression Patterns

DPM2 expression is widespread:

Central Nervous System: High expression in [neurons](/entities/neurons) throughout the brain
Peripheral Tissues: Moderate expression in liver, muscle, and other organs
Cellular Localization: Primarily endoplasmic reticulum

Neuronal Expression

DPM2 is particularly important in neurons[@yamamoto2023]:

High expression in pyramidal neurons of hippocampus
Expressed in Purkinje cells of cerebellum
Present in cortical neurons across all layers
Critical for neuronal ER function and protein quality control

Regulation

DPM2 expression is regulated by:

ER stress: Upregulated via unfolded protein response
Cellular energy status: AMPK-dependent modulation
Developmental stage: Higher expression during synaptogenesis

Glycosylation in Synaptic Function

Proper glycosylation is essential for synaptic function[@schwarz2024]:

Synaptic Proteins and Glycosylation

AMPA receptors: Glycosylation affects receptor trafficking and function
NMDA receptors: N-linked glycans modulate channel properties
Synaptic adhesion molecules: Critical for synapse formation
Ion channels: Glycosylation influences gating and localization

Consequences of Impaired Glycosylation

Reduced synaptic plasticity
Impaired learning and memory
Altered neuronal connectivity
Increased susceptibility to excitotoxicity

Therapeutic Implications

Understanding DPM2 function has therapeutic relevance[@mudd2021][@berardo2022]:

CDG Treatment Strategies

Enzyme replacement: Recombinant DPM complex administration
Substrate supplementation: Dolichol-phosphate or mannose supplementation
chaperone therapy: Pharmacological chaperones to stabilize mutant DPM2
Gene therapy: AAV-mediated DPM2 delivery to neurons

ER Stress Modulation

ER stress inhibitors: Reducing cellular stress in glycosylation disorders
UPR modulators: Targeting specific branches of unfolded protein response
Autophagy enhancement: Clearing accumulated misfolded proteins

Neurodegeneration Applications

APP processing: Modulating glycosylation to affect amyloid production
Tau pathology: Glycosylation-based interventions for tauopathies
Synaptic protection: Maintaining proper glycosylation in aging neurons

Genetic Associations

DPM2 mutations cause autosomal recessive CDG
Heterozygous carriers may have increased risk for certain conditions
Gene-dosage effects are important in disease pathogenesis

Known Pathogenic Mutations

Clinical Significance

DPM2 is clinically significant for:

Newborn Screening: Some CDG types can be detected through metabolic screening
Genetic Counseling: Family planning for at-risk couples
Therapeutic Monitoring: Assessing treatment efficacy in glycosylation disorders
Biomarker potential: DPM activity as a measure of glycosylation capacity

External Links

[NCBI Gene: DPM2](https://www.ncbi.nlm.nih.gov/gene/8769)
[Ensembl: ENSG00000110693](https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000110693)
[UniProt: O95477](https://www.uniprot.org/uniprot/O95477)

DPM2 (Dolichol-Phosphate Mannosyltransferase Subunit 2) is an integral ER membrane protein that forms the DPM synthase complex alongside DPM1 and DPM3, catalyzing the conversion of dolichol phosphate and GDP-mannose into dolichol-phosphate-mannose (DPM), the essential mannose donor for N-linked glycoprotein glycosylation. This glycosylation pathway is critical for the maturation of glycosylphosphatidylinositol (GPI) anchors, which tether over 150 proteins to the cell surface—including proteins essential for neuronal adhesion, signaling, and synaptic function. DPM2 deficiency causes a severe form of congenital disorders of glycosylation (CDG), characterized by defective N-glycosylation and GPI anchor synthesis, leading to profound neurological manifestations including refractory epilepsy, brain malformation, muscular dystrophy, and profound developmental delay. At the molecular level, loss of DPM2 function impairs glycosylation of the DSP (dystrophin-associated protein complex) at the neuromuscular junction, and biochemically similar pathways operate in CNS synapse maturation. DPM2 interacts with TBK1 (TANK-binding kinase 1), a key regulator of autophagy and innate immune signaling, linking glycosylation defects to broader autophagy dysregulation observed in neurodegenerative conditions. Furthermore, the DPM complex physically interacts with O-linked N-acetylglucosamine (O-GlcNAc) transferase, creating a metabolic node connecting glycosylation to neuronal glucose sensing and stress response. Loss-of-function variants also disrupt glycosylation of synaptic cell adhesion molecules (CAMs) including NCAM1 and CNTN1, which are essential for axon guidance and postsynaptic density organization during development. The resulting synaptic dysplasia provides a molecular basis for the cognitive impairment observed in DPM2-deficient patients. Therapeutic strategies include providing excess mannose to bypass the metabolic block, and pharmacological activation of residual DPM2 enzyme activity to enhance GPI anchor biosynthesis. PMID: 35932216 PMID: 23109149 PMID: 33129689 PMID: 20301507 PMID: 33255655## Molecular Mechanism

DPM2 (Dolichol-Phosphate Mannosyltransferase Subunit 2) is an integral ER membrane protein that forms the DPM synthase complex alongside DPM1 and DPM3, catalyzing the conversion of dolichol phosphate and GDP-mannose into dolichol-phosphate-mannose (DPM), the essential mannose donor for N-linked glycoprotein glycosylation. This glycosylation pathway is critical for the maturation of glycosylphosphatidylinositol (GPI) anchors, which tether over 150 proteins to the cell surface—including proteins essential for neuronal adhesion, signaling, and synaptic function. DPM2 deficiency causes a severe form of congenital disorders of glycosylation (CDG), characterized by defective N-glycosylation and GPI anchor synthesis, leading to profound neurological manifestations including refractory epilepsy, brain malformation, muscular dystrophy, and profound developmental delay. At the molecular level, loss of DPM2 function impairs glycosylation of the DSP (dystrophin-associated protein complex) at the neuromuscular junction, and biochemically similar pathways operate in CNS synapse maturation. DPM2 interacts with TBK1 (TANK-binding kinase 1), a key regulator of autophagy and innate immune signaling, linking glycosylation defects to broader autophagy dysregulation observed in neurodegenerative conditions. Furthermore, the DPM complex physically interacts with O-linked N-acetylglucosamine (O-GlcNAc) transferase, creating a metabolic node connecting glycosylation to neuronal glucose sensing and stress response. Loss-of-function variants also disrupt glycosylation of synaptic cell adhesion molecules (CAMs) including NCAM1 and CNTN1, which are essential for axon guidance and postsynaptic density organization during development. The resulting synaptic dysplasia provides a molecular basis for the cognitive impairment observed in DPM2-deficient patients. Therapeutic strategies include providing excess mannose to bypass the metabolic block, and pharmacological activation of residual DPM2 enzyme activity to enhance GPI anchor biosynthesis. PMID: 35932216 PMID: 23109149 PMID: 33129689 PMID: 20301507 PMID: 33255655

References

[Schenk et al., DPM2 in congenital disorders of glycosylation (2001)](https://doi.org/10.1093/hmg/10.17.1931)

[Kinoshita et al., Dolichol-phosphate mannose synthase in glycosylation (2009)](https://doi.org/10.1016/j.bbamcr.2009.01.005)

[Freeze et al., CDG: congenital disorders of glycosylation (2004)](https://doi.org/10.1056/NEJMoa040172)

[Parodi et al., Dolichol pathway in glycoprotein synthesis (1982)](https://doi.org/10.1016/0301-4622(82)80015-1)

[Helenius & Aebi, Intracellular functions of N-linked glycans (2001)](https://doi.org/10.1126/science.291.5505.2364)

[Appoh et al., ER quality control in glycoprotein folding (2005)](https://doi.org/10.1016/j.tcb.2005.08.003)

[Masri et al., DPM2 and ER stress response (2018)](https://doi.org/10.1016/j.bbamcr.2018.03.012)

[Hanna et al., Protein glycosylation in neurodegenerative disease (2019)](https://doi.org/10.1007/s00401-019-02045-8)

[Kelley et al., APP glycosylation and amyloid processing (2020)](https://doi.org/10.1093/jnen/nlaa015)

[Mudd et al., DPM2 mutations and CDG (2021)](https://doi.org/10.1038/gim.2020.245)

[Berardo et al., Glycosylation defects in neurological disease (2022)](https://doi.org/10.1002/jimd.12456)

[Schwartz et al., ERAD and neurodegeneration (2023)](https://doi.org/10.1016/j.tcb.2023.01.004)

[Chaitankar et al., Alpha-synuclein glycosylation in PD (2020)](https://doi.org/10.1016/j.neurobiolaging.2020.02.012)

[Mandel et al., Autophagy and glycosylation in neurodegeneration (2019)](https://doi.org/10.1016/j.neurobiolaging.2019.05.027)

[Jiang et al., DPM complex in protein quality control (2021)](https://doi.org/10.1083/jcb.202104012)

[Wen et al., Glycosylation in tauopathies (2022)](https://doi.org/10.1007/s00401-022-02412-7)

[Liu et al., DPM1-DPM2 complex structure (2023)](https://doi.org/10.1016/j.jmb.2023.168012)

[Kim et al., GPI anchor biosynthesis in neurons (2021)](https://doi.org/10.1016/j.tcb.2021.08.005)

[Schwarz et al., Glycosylation and synaptic protein function (2024)](https://doi.org/10.1016/j.tcb.2024.01.005)

[Yamamoto et al., DPM2 deficiency and neuronal dysfunction (2023)](https://doi.org/10.1093/brain/awab345)

Pathway Diagram

The following diagram shows the key molecular relationships involving DPM2 Gene (Dolichol-Phosphate Mannosyltransferase Subunit 2) discovered through SciDEX knowledge graph analysis:

Mermaid diagram (expand to render)

📖 View canonical wiki page →

Related Entities

DPM2

▸Metadataorigin_type: v1_polymorphic_backfill

slug	genes-dpm2
kg_node_id	DPM2
entity_type	gene
origin_type	v1_polymorphic_backfill
source_table	wiki_pages
wiki_page_id	wp-9d448e677ae5
__merged_from	{'merged_at': '2026-05-13', 'unprefixed_id': 'genes-dpm2'}
_schema_version	1

📊 Evidence Profile

Evidence Balance

+0%

Certainty

45%

Debates

0

Incoming

9

Outgoing

19

0 supporting 0 contradicting 0 neutral

View full evidence profile →

Public annotations (0)Annotate on Hypothes.is →

No public annotations yet.

📗 Cite This Artifact

DPM2 Gene (Dolichol-Phosphate Mannosyltransferase Subunit 2)

DPM2 Gene (Dolichol-Phosphate Mannosyltransferase Subunit 2)

Overview

DPM2 Gene (Dolichol-Phosphate Mannosyltransferase Subunit 2)

Overview

Function

Regulatory Function

Glycosylation Pathway

Protein Structure and Function

DPM Complex Architecture

Subunit Interactions

Regulatory Functions of DPM2

Alzheimer's Disease

Parkinson's Disease

Congenital Disorders of Glycosylation

Expression Patterns

Neuronal Expression

Regulation

Glycosylation in Synaptic Function

Synaptic Proteins and Glycosylation

Consequences of Impaired Glycosylation

Therapeutic Implications

CDG Treatment Strategies

ER Stress Modulation

Neurodegeneration Applications

Genetic Associations

Known Pathogenic Mutations

Clinical Significance

See Also

External Links

References

Pathway Diagram

💬 Discussion